Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 3, 2014, Pages 312-320

  Byun, Ja Min ^a   Lee, Chang Kyun ^a   Rhee, Sang Youl ^a   Kim, Hyo Jong ^a   Im, Jong Pil ^b   Park, Dong Il ^c   Eun, Chang Soo ^d   Jung, Sung Ae ^e   Shin, Jeong Eun ^f   Lee, Kang Moon ^g   Cheon, Jae Hee ^h  

^a Kyung Hee University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Hanyang University Guri Hospital   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Dankook University College of Medicine   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

Author keywords

Inflammatory bowel disease; Latent tuberculosis infection; Tuberculosis; Tumor necrosis factor inhibitor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; KOREA; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; STANDARDIZED INCIDENCE RATIO; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS CONTROL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INFLAMMATORY BOWEL DISEASES; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; RISK ASSESSMENT; SOUTH KOREA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84922702492     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.1000960     Document Type: Article

References (37)

1. Economou M, Pappas G. New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008;14:709-20.
2. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266-80.
3. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010;18:237.
4. Bygbjerg IC. Double burden of noncommunicable and infectious diseases in developing countries. Science 2012;337:1499-501.
5. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-7.
6. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
7. ColombelJF,SandbornWJ,Rutgeerts P,EnnsR,HanauerSB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
8. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
10. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
11. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884-94.
12. Abreu C, Magro F, Santos-Antunes J, Pilão A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486-92.
13. Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013;7:208-12.
14. Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 2014;8:550-7.
15. Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, et al. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 2014;17:291-8.
16. Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, et al. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241-7.
17. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. MEDrang Inc; Seoul: 2011.
18. Korean Statistical Information Service [2010 Population and Housing Census Wes site]. August 19 2011. Available from https://www.census.go.kr. Accessed 1 June 2014.
19. Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 2013;191:565-71.
20. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4.
21. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
22. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort intheUnitedStates. InflammBowelDis2011;17:77-83.
23. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-68.
24. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States. 2010. MMWR Recomm Rep 2010;59:1-25.
25. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-alpha inhibitor. Korean J Intern Med 2013;28:174-9.
26. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007;7:328-37.
27. Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012;54:211-19.
28. Lillebaek T, Kok-Jensen A, Viskum K. Bacillarity at autopsy in pulmonary tuberculosis. Mycobacterium tuberculosis is often disseminated. APMIS 2002;110:625-9.
29. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1-51.
30. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
31. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87.
32. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
33. American Gastroenterology Association. Adult IBD physician performance measures set [AGAWeb site]. October 26 2011. Available from http://www.gastro.org/practice/quality-initiatives/IBD-Measures.pdf. Assessed 12 September 2014.
34. Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, et al. Quality indicators for in flammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis 2013;19:662-8.
35. Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis 2012;18:1057-63.
36. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36.
37. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT™ registry. Am J Gastroenterol 2012;107:1409-22.